Companies Dominating the Choroideremia Treatment Landscape
- Novartis AG
- Spark Therapeutics
- Bluebird Bio Inc.
- Biogen Inc.
- Copernicus Therapeutics, Inc.
- 4D Molecular Therapeutics
- Wize Pharma Inc.
- Retina Implant AG
- Hoffmann-La Roche Ltd
- Kiora Pharmaceuticals
- Astellas Pharma Inc.
- Pixium Vision
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of choroideremia treatment is evaluated at USD 9.81 billion.
The choroideremia treatment market size was over USD 9.43 billion in 2024 and is poised to exceed USD 17.35 billion by 2037, witnessing over 4.8% CAGR during the forecast period i.e., between 2025-2037. Growing prevalence of choroideremia and growing advancement in medical technology will boost the market growth.
North America industry is set to hold largest revenue share of 35% by 2037, due to rising substantial innovation in healthcare infrastructure in the region.
The major players in the market are Biogen, Copernicus Therapeutics, Inc., 4D Molecular Therapeutics, Wize Pharma Inc., Retina Implant AG, Hoffmann-La Roche Ltd, and others.
